Recensioni verificate Soddisfatta del servizio.
Personale disponibile e gentile. Lo consiglio a tutti ...
Cliente Sorgente Genetica
logomysorgente

02  4948  5291

  • Cos'è AURORA

    Aurora è il test di screening prenatale di ultima generazione 
    sicuro, affidabile,
    veloce e precoce

  • Sicuro

    Grazie a un semplice prelievo di sangue materno
    eviti il rischio di aborto di tecniche invasive come amniocentesi o villocentesi

  • Affidabile

    Oltre il 99,9% di affidabilità nel rilevare
    la trisomia 21, responsabile
    della Sindrome di Down

  • Precoce e veloce

    icona svegliaIndividuare precocemente la presenza di anomalie cromosomiche è fondamentale:
    puoi effettuare Aurora dalla 10ª settimana

    icona documentoIl test è veloce: risultati in 7-10 giorni lavorativi con la percentuale di test da ripetere più bassa del mercato: 0,1%

  • La serenità della mamma
    in 3 semplici passi

    icotelefona

    Prenota il test

    icoesami

    Fai un prelievo di sangue

    icoginecologo

    Leggi i risultati

  • Test diagnosi prenatale non invasivo
  • 151126 banner Aurora mobile 01
  • 151126 banner Aurora mobile 02
  • 151126 banner Aurora mobile 03
  • slide mobile03
cover cartoon
cover venturetti

Ultime notizie dal mondo della genetica


The first attempt at genetic editing was done in vivo

In the future, will it be possible to correct a genetic error directly in the body? Maybe yes. The scientists at the Oakland Benioff Hospital have applied gene therapy to a man with Hunter's disease. If all goes well, the body will incorporate the correct version of the defective gene, hence a regression of the disease.

In standard gene therapy, offensive viruses are used to replace diseased genes with their correct versions. Usually, scientists apply the procedure on a cell culture of the patient, to be re-planted at a later time. In this case, instead, they used genetic editing directly in the patient's body.

Scientists have operated a man suffering from a disease called mucopolysacaridosis type 2, or Hunter's disease. Those who suffer from it accumulate sugars in the organelles of the cells, all because of a chronic scarcity of the enzyme Ids. In the long term, the accumulations of sugar cause problems of sight, hearing, heart. To date, the only available treatment is weekly enzyme infusion, but gene therapy may make it unnecessary.

Phases 1 and 2 of the experiment are intended to verify the safety of the treatment. Only at this point will you go to Stage 3, which will serve to verify its effectiveness. For this purpose, researchers have already recruited 9 other patients with the disease who will undergo short-term surgery. In addition, similar experiments are ongoing for type B hemophilia and type 1 mucopolysaccharides, or Hurler-Scheie syndrome. The criterion used is always the same.

Source: ansa.it

Link social

Link social